RG 6146

Drug Profile

RG 6146

Alternative Names: RG6146; RO 6870810; TEN 010

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tensha Therapeutics
  • Developer Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Diffuse large B cell lymphoma; Multiple myeloma; Ovarian cancer
  • No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Second-line therapy or greater) in USA (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top